Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 5/2019

SECOND TRIMESTER ABORTION: MIFEPRISTONE PLUS MISOPROSTOL vs. MISOPROSTOL PLUS OXYTOCIN

AIDA PETCA 1#, MONA ZVANCA 1#, MIHAELA BOȚ 1, RAZVAN-COSMIN PETCA 2*, CLAUDIA MEHEDINȚU 3, SILVIUS NEGOIȚA 4#, NICOLETA MARU 5

1.Department of Obstetrics and Gynaecology, Elias Emergency Hospital, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2 .Department of Urology, “Prof. Dr. Th. Burghele” Clinical Hospital “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
3 .Department of Obstetrics and Gynaecology, Malaxa Clinical Hospital, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
4 .Department of Anaesthesiology and Critical Care, Elias Emergency Hospital, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
5 .Department of Anatomy, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Download Full Article PDF

The study compares outcomes from simultaneous administration of Mifepristone and Misoprostol (M&M) with a regimen in which Misoprostol is associated with Oxytocin (M&O) for second-trimester abortion. The primary outcome was uterine evacuation within 12 hours after the first Misoprostol dose, secondary outcomes were adverse effects, post-abortion complications and average cost per patient for each method. 108 patients were enrolled with equal distribution and abortion was complete in both groups. In the M&M group the induction-abortion interval (I-AI) was less than 12 hours in 62.96% (n = 34) compared with the M&O group with 22.22% (n = 12), p < 0.05. Both regimens had high acceptability rates. We did not find any statistical difference in adverse effects observed between the two groups. Administering M&M simultaneously resulted in grater expulsion rates within 12 hours compared with M&O, with the latter regimen demonstrating synergistic benefits, with lower expenses and satisfactory I-AI.